MARKET

MNMD

MNMD

Mind Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6517
+0.0715
+12.32%
Pre Market: 0.6999 +0.0482 +7.40% 08:43 08/11 EDT
OPEN
0.6200
PREV CLOSE
0.5802
HIGH
0.6600
LOW
0.5974
VOLUME
89.09K
TURNOVER
--
52 WEEK HIGH
3.180
52 WEEK LOW
0.5301
MARKET CAP
275.31M
P/E (TTM)
-2.8760
1D
5D
1M
3M
1Y
5Y
MindMed initiated at overweight at Cantor Fitzgerald; sees 417% upside
Cantor Fitzgerald initiated MindMed (NASDAQ:MNMD) at overw...
Seekingalpha · 21h ago
--Cantor Fitzgerald Starts Mind Medicine at Overweight With $3 Price Target
--Cantor Fitzgerald Starts Mind Medicine at Overweight With $3 Price Target
MT Newswires · 1d ago
Cybin, Field Trip Health Among Top Psychedelic Movers Of Today
 
Benzinga · 1d ago
GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 29.83% at $15.80
Benzinga · 5d ago
Key Biotech Company Goes All The Way To Reverse Share Split, Here's What We Know
Psychedelics appear to be here to stay. Yet stocks, shares and finance are another story. On August 4, publicly traded clinical-stage psychedelics firm Mind Medicine Inc.
Benzinga · 5d ago
Mind Medicine announces 1-for-15 reverse stock split
Mind Medicine (NASDAQ:MNMD) on Thursday announced a <a href...
Seekingalpha · 6d ago
MindMed Board of Directors Approves Reverse Share Split
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio o...
PR Newswire · 6d ago
Psychedelic Stock Gainers And Losers From August 4, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 10.64% at $12.17
Benzinga · 6d ago
More
No Data
Learn about the latest financial forecast of MNMD. Analyze the recent business situations of Mind Medicine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MNMD stock price target is 5.75 with a high estimate of 10.00 and a low estimate of 3.000.
High10.00
Average5.75
Low3.000
Current 0.6517
EPS
Actual
Estimate
-0.07-0.05-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 164
Institutional Holdings: 48.47M
% Owned: 11.47%
Shares Outstanding: 422.44M
TypeInstitutionsShares
Increased
33
1.84M
New
27
697.69K
Decreased
40
4.62M
Sold Out
47
1.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
President/Director
Miriam Wernli
Chief Executive Officer/Director
Robert Barrow
Non-Executive Vice Chairman/Independent Director
Andreas Krebs
Chief Financial Officer
Schond Greenway
Other
Daniel Karlin
Other
Francois Lilienthal
Secretary
Cynthia Hu
Non-Executive Director/Independent Director
Carol Vallone
Independent Director
Brigid Makes
No Data
No Data
About MNMD
Mind Medicine (MindMed) Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The Company is developing a pipeline of drug candidates, targeting the serotonin, dopamine and acetylcholine systems. This specifically includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes, including lysergic acid diethylamide (LSD), R(-)-methylenedioxymethamphetamine (MDMA) and zolunicant, or 18-methoxycoronaridine (MC), a congener of ibogaine. The Company’s subsidiaries include Mind Medicine, Inc. (MindMed US), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH.

Webull offers kinds of Mind Medicine (MindMed) Inc stock information, including NASDAQ:MNMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNMD stock methods without spending real money on the virtual paper trading platform.